I. The Plasma Cell Dyscrasias.- 1. A perspective of plasma cell dyscrasias: clinical implications of monoclonal light chains in renal disease.- 2. Genotypic and phenotypic diversity of plasma cell myeloma.- 3. Immunoglobulin synthesis in plasma cell dyscrasias with renal lesions.- 4. Renal amyloidosis: new perspectives.- 5. Amyloidogenesis and light chains.- 6. Physiopathological aspects of plasma cell dyscrasias.- II. Light Chain Nephrotoxicity.- 1. Glomerular and associated tubular injury by light chains. The spectrum of damage and effect of treatment.- 2. Effect of light chains on proximal tubule function.- 3. Pathophysiological aspects of myeloma cast nephropathy.- 4. Light chain nephrotoxicity: insights from a rat model of myeloma.- 5. Light chain-related tubulointerstitial nephropathy.- 6. The pathogenesis of cast nephropathy.- 7. Light chain nephrotoxicity.- III. The Kidney Involvement in Plasma Cell Dyscrasias.- 1. Kidney in multiple myeloma and related disorders.- 2. Histological, histochemical and ultrastructural features of myeloma kidney.- 3. Monoclonal immunoglobulin deposition disease: immunopathologic aspects of renal involvement.- 4. The glomerulonephritis of essential mixed cryoglobulinemia.- 5. Clinical spectrum of tubular disorders from light chains.- 6. Renal amyloidosis — Retrospective collaborative study.- 7. Kidney involvement in light chain deposition disease.- 8. Some aspects of kidney involvement in plasma cell dyscrasias.- IV. The Therapeutic Approach.- 1. Controlled trial of plasma exchange in rapidly progressive renal failure.- 2. Prevention and treatment of hyperviscosity syndrome.- 3. Implications of renal failure in mUltiple myeloma.- 4. Uraemia in myeloma: management and prognosis.- 5. Therapeutic prospects in amyloidosis.- 6. Sundrieson therapy of multiple myeloma and amyloidosis and their renal consequences.- V..- Conclusions.- Index of subjects.